A Phase 1 interventional study of Romosozumab and Placebo in Osteopenia, sponsored by Amgen. Completed. Open to participants aged 45 Years to 59 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-05.
Sponsored by Amgen · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing romosozumab in Bone Diseases, Metabolic — none open to participants now, 1 under way, none of them phase 3. romosozumab · Bone Diseases, Metabolic.
Among the 11 studies testing romosozumab in Bone Diseases, Metabolic, this one is the 6th largest by enrollment, is the only one that started in 2006, is one of 4 in phase 1, and was the 3rd registered.
662 studies on the registry are indexed under Bone Diseases, Metabolic; 94 are open to participants now.
Browse Bone Diseases, Metabolic studies →None of the 11 studies testing romosozumab in Bone Diseases, Metabolic is open now. The open studies under Bone Diseases, Metabolic, anywhere →
romosozumab: first FDA approval 2019 (EVENITY), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 64 Bone Diseases, Metabolic studies recruiting now, 28 (44%) set no upper age limit and 28 (44%) stop at 75 or younger; 12 take children under 18; 22 take healthy volunteers.
This study: 45 Years to 59 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2006.
This study's enrollment of 74 is above the median of 60 across 509 interventional studies indexed under Bone Diseases, Metabolic.
Median enrollment 74 across the 11 interventional studies. Of the 10 that completed or were terminated, 10 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 11 have an industry lead sponsor. The 3 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
23 studies in Bone Diseases, Metabolic by Amgen: none open now, none under way, none of them phase 3. Of 23 finished, 21 (91%) have results posted.
Among the 23 studies in Bone Diseases, Metabolic by Amgen, this one is the 15th largest by enrollment, is one of 3 that started in 2006, is one of 7 in phase 1, and was the 15th registered.
Amgen’s Bone Diseases, Metabolic studies by the year they started, since 2002.
1 of the studies testing romosozumab in Bone Diseases, Metabolic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05058976Susan L. GreenspanRomosozumab Use to Build Skeletal Integrity | 2027-03-31 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies testing romosozumab in Bone Diseases, Metabolic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 23 in Bone Diseases, Metabolic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to assess the safety and tolerability of romosozumab following single dose subcutaneous (SC) or intravenous (IV) administration in healthy men and postmenopausal women.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants were randomized to receive a single dose of matching placebo administered by subcutaneous or intravenous injection.
Drug: Placebo
Participants were randomized to receive a single dose of romosozumab administered by subcutaneous or intravenous injection. The starting dose was 0.1 mg/kg, with sequential escalation up to 10 mg/kg.
Drug: Romosozumab
Administered subcutaneously or intravenously
Also known as: AMG 785, EVENITY™
Administered subcutaneously or intravenously
Number of Participants With Adverse Events
Serious adverse events were any events that were fatal, were life-threatening (placed the participant at immediate risk of death), required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, were congenital anomalies or birth defects, or were other significant medical hazards. Relatedness to investigational product was assessed by the investigator by means of the question: "Is there a reasonable possibility that the event may have been caused by the investigational product?'
Time frame: Adverse events were collected from the first dose of treatment up until day 29 for the 0.1 mg/kg and 0.3 mg/kg SC treatment groups, up to 57 days for the 1 mg/kg and 3 mg/kg IV/SC groups and for up to 85 days for the 5 mg/kg and 10 mg/kg SC/IV groups.
Number of Participants Who Developed Anti-romosozumab Antibodies
Binding anti-romosozumab antibody titers were assessed using a validated electrochemiluninescence (ECL) immunoassay. The limit of detection for this assay was 3.91 ng/mL of anti-romosozumab antibody in neat serum. Samples found to be positive for binding antibodies were further tested using a validated bioassay to determine if the antibodies were able to neutralize the activity of romosozumab. The limit of detection for this assay was ≥ 0.75 μg/mL.
Time frame: Day 29 (all participants), day 57 (1, 3, 5, and 10 mg/kg treatment groups only) and at day 85 (5 and 10 mg/kg teatment groups only).
Maximum Observed Concentration (Cmax) of Romosozumab
Time frame: Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.
Time to Maximum Observed Concentration (Tmax) of Romosozumab
Time frame: Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.
Initial Concentration Following IV Administration (C0) of Romosozumab
Time frame: Day 1 at the end of infusion
Area Under the Serum Concentration-time Curve From Time Zero to Infinity for Romosozumab
Time frame: Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.
Apparent Clearance (CL/F) / Clearance (CL) for Romosozumab
Time frame: Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.
Half-life Associated With the Beta (Plateau) Phase of Elimination for Romosozumab
The plateau (beta, β) phase half-life (t½,β) was calculated from the natural log of 2 divided by the beta phase rate constant (λβ). λβ for a subject was estimated by linear regression of at least 3 contiguous time points that followed the Cmax and constituted a distinct phase that preceded the terminal phase.
Time frame: Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.
Half-life Associated With the Gamma (Terminal) Phase of Elimination for Romosozumab
The terminal (gamma, γ) phase half-life (t½,γ) was calculated from the natural log of 2 divided by the terminal rate constant (λz).
Time frame: Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.
Maximum Effect for Serum Type 1 Aminoterminal Propeptide (P1NP)
Defined as the maximum value postdose.
Time frame: Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.
Time to Maximum Effect of P1NP
Defined as the time to maximum value postdose.
Time frame: Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.
Area Under the Curve From Day 0 to Day 29 (AUC0-29) for P1NP
Time frame: Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.
Area Under the Curve From Day 0 to the Last Sampling Time Point (AUC0-t) for P1NP
Time frame: Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab,
Maximum Effect for Serum C-telopeptide (sCTX)
Defined as the minimum value postdose.
Time frame: Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.
Time to Maximum Effect of sCTX
Defined as the time to minimum value postdose.
Time frame: Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.
Area Under the Curve From Day 0 to Day 29 (AUC0-29) for sCTX
Time frame: Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.
Area Under the Curve From Day 0 to the Last Sampling Time Point (AUC0-t) for sCTX
Time frame: Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.
Maximum Effect for Osteocalcin
Defined as the maximum value postdose.
Time frame: Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.
Time to Maximum Effect of Osteocalcin
Defined as the time to maximum value postdose.
Time frame: Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.
Area Under the Curve From Day 0 to Day 29 (AUC0-29) for Osteocalcin
Time frame: Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.
Area Under the Curve From Day 0 to the Last Sampling Time Point (AUC0-t) for Osteocalcin
Time frame: Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.
Maximum Effect for Bone-specific Alkaline Phosphatase (BSAP)
Defined as the maximum value postdose.
Time frame: Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.
Time to Maximum Effect of BSAP
Defined as the time to maximum value postdose.
Time frame: Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.
Area Under the Curve From Day 0 to Day 29 (AUC0-29) for BSAP
Time frame: Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.
Area Under the Curve From Day 0 to the Last Sampling Time Point (AUC0-t) for BSAP
Time frame: Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.
Maximum Effect for Intact Parathyroid Hormone (iPTH)
Defined as the maximum value postdose.
Time frame: Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.
Time to Maximum Effect of iPTH
Defined as the time to maximum value postdose.
Time frame: Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.
Area Under the Curve From Day 0 to Day 29 (AUC0-29) for iPTH
Time frame: Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.
Area Under the Curve From Day 0 to the Last Sampling Timepoint (AUC0-t) for iPTH
Time frame: Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.
Percent Change From Baseline in Sclerostin
Time frame: Baseline and days 15, 29, 43, 57, 71, and 85
Serum Calcium Over Time
Time frame: Dday 1 predose and at 4, 6, 8, 10, and 12 hours, days 2, 3, 4, 5, 6, 8, 11, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, and 85
Ionized Calcium Over Time
Time frame: Day 1 predose and at 4, 6, 8, 10, 12 hours, days 2, 3, 4, 5, 6, 8, 11, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, and 85
This was a single-center study conducted in the USA. The first participant enrolled on 13 December 2006 and the last participant completed the study on 06 July 2007.
| Milestone | Placebo SC | Romosozumab 0.1 mg/kg SC | Romosozumab 0.3 mg/kg SC | Romosozumab 1.0 mg/kg SC | Romosozumab 3.0 mg/kg SC | Romosozumab 5.0 mg/kg SC | Romosozumab 10.0 mg/kg SC | Placebo IV | Romosozumab 1.0 mg/kg IV | Romosozumab 5.0 mg/kg IV |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 14 | 6 | 8 | 9 | 6 | 9 | 6 | 4 | 6 | 6 |
| Received study drug | 14 | 6 | 6 | 9 | 6 | 9 | 6 | 4 | 6 | 6 |
| Completed | 14 | 6 | 6 | 9 | 6 | 9 | 6 | 4 | 6 | 6 |
| Not completed | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Serious adverse events were any events that were fatal, were life-threatening (placed the participant at immediate risk of death), required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, were congenital anomalies or birth defects, or were other significant medical hazards. Relatedness to investigational product was assessed by the investigator by means of the question: "Is there a reasonable possibility that the event may have been caused by the investigational product?'
| Participants | Placebo SC | Romosozumab 0.1 mg/kg SC | Romosozumab 0.3 mg/kg SC | Romosozumab 1.0 mg/kg SC | Romosozumab 3.0 mg/kg SC | Romosozumab 5.0 mg/kg SC | Romosozumab 10.0 mg/kg SC | Placebo IV | Romosozumab 1.0 mg/kg IV | Romosozumab 5.0 mg/kg IV |
|---|---|---|---|---|---|---|---|---|---|---|
| Any adverse event | 9 | 4 | 4 | 1 | 5 | 6 | 5 | 2 | 1 | 2 |
| Serious adverse events | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Treatment-related adverse events | 5 | 4 | 2 | 0 | 3 | 4 | 5 | 0 | 1 | 1 |
| Serious treatment-related adverse events | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Discontinuations due to adverse events | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deaths | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Binding anti-romosozumab antibody titers were assessed using a validated electrochemiluninescence (ECL) immunoassay. The limit of detection for this assay was 3.91 ng/mL of anti-romosozumab antibody in neat serum. Samples found to be positive for binding antibodies were further tested using a validated bioassay to determine if the antibodies were able to neutralize the activity of romosozumab. The limit of detection for this assay was ≥ 0.75 μg/mL.
| participants | Placebo SC | Romosozumab 0.1 mg/kg SC | Romosozumab 0.3 mg/kg SC | Romosozumab 1.0 mg/kg SC | Romosozumab 3.0 mg/kg SC | Romosozumab 5.0 mg/kg SC | Romosozumab 10.0 mg/kg SC | Placebo IV | Romosozumab 1.0 mg/kg IV | Romosozumab 5.0 mg/kg IV |
|---|---|---|---|---|---|---|---|---|---|---|
| Binding antibody positive | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 0 | 0 | 2 |
| Neutralizing antibody positive | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| ng/mL | Romosozumab 0.1 mg/kg SC | Romosozumab 0.3 mg/kg SC | Romosozumab 1.0 mg/kg SC | Romosozumab 3.0 mg/kg SC | Romosozumab 5.0 mg/kg SC | Romosozumab 10.0 mg/kg SC |
|---|---|---|---|---|---|---|
| Maximum Observed Concentration (Cmax) of Romosozumab | 375 ± 182 | 1280 ± 653 | 4890 ± 1780 | 21300 ± 5170 | 33500 ± 8290 | 75200 ± 15900 |
| days | Romosozumab 0.1 mg/kg SC | Romosozumab 0.3 mg/kg SC | Romosozumab 1.0 mg/kg SC | Romosozumab 3.0 mg/kg SC | Romosozumab 5.0 mg/kg SC | Romosozumab 10.0 mg/kg SC |
|---|---|---|---|---|---|---|
| Time to Maximum Observed Concentration (Tmax) of Romosozumab | 1.5 (0.5 to 7) | 2.5 (2 to 5) | 3 (2 to 14) | 5 (4 to 7) | 5 (3 to 7) | 4.5 (2 to 7) |
| ng/mL | Romosozumab 1.0 mg/kg IV | Romosozumab 5.0 mg/kg IV |
|---|---|---|
| Initial Concentration Following IV Administration (C0) of Romosozumab | 24900 ± 4670 | 132000 ± 13700 |
| µg*hr/mL | Romosozumab 0.1 mg/kg SC | Romosozumab 0.3 mg/kg SC | Romosozumab 1.0 mg/kg SC | Romosozumab 3.0 mg/kg SC | Romosozumab 5.0 mg/kg SC | Romosozumab 10.0 mg/kg SC | Romosozumab 1.0 mg/kg IV | Romosozumab 5.0 mg/kg IV |
|---|---|---|---|---|---|---|---|---|
| Area Under the Serum Concentration-time Curve From Time Zero to Infinity for Romosozumab | 78.5 ± 22.6 | 288 ± 144 | 1480 ± 605 | 8170 ± 1810 | 16900 ± 4350 | 43400 ± 8550 | 3020 ± 989 | 24400 ± 4400 |
| mL/hr/kg | Romosozumab 0.1 mg/kg SC | Romosozumab 0.3 mg/kg SC | Romosozumab 1.0 mg/kg SC | Romosozumab 3.0 mg/kg SC | Romosozumab 5.0 mg/kg SC | Romosozumab 10.0 mg/kg SC | Romosozumab 1.0 mg/kg IV | Romosozumab 5.0 mg/kg IV |
|---|---|---|---|---|---|---|---|---|
| Apparent Clearance (CL/F) / Clearance (CL) for Romosozumab | 1.39 ± 0.489 | 1.35 ± 0.841 | 0.873 ± 0.647 | 0.383 ± 0.0901 | 0.319 ± 0.0998 | 0.236 ± 0.0370 | 0.362 ± 0.117 | 0.210 ± 0.0361 |
The plateau (beta, β) phase half-life (t½,β) was calculated from the natural log of 2 divided by the beta phase rate constant (λβ). λβ for a subject was estimated by linear regression of at least 3 contiguous time points that followed the Cmax and constituted a distinct phase that preceded the terminal phase.
| days | Romosozumab 0.1 mg/kg SC | Romosozumab 0.3 mg/kg SC | Romosozumab 1.0 mg/kg SC | Romosozumab 3.0 mg/kg SC | Romosozumab 5.0 mg/kg SC | Romosozumab 10.0 mg/kg SC | Romosozumab 1.0 mg/kg IV | Romosozumab 5.0 mg/kg IV |
|---|---|---|---|---|---|---|---|---|
| Half-life Associated With the Beta (Plateau) Phase of Elimination for Romosozumab | — | — | — | 11.1 ± 3.70 | 12.9 ± 3.14 | 18.0 ± 3.54 | — | 10.6 ± 1.70 |
The terminal (gamma, γ) phase half-life (t½,γ) was calculated from the natural log of 2 divided by the terminal rate constant (λz).
| days | Romosozumab 0.1 mg/kg SC | Romosozumab 0.3 mg/kg SC | Romosozumab 1.0 mg/kg SC | Romosozumab 3.0 mg/kg SC | Romosozumab 5.0 mg/kg SC | Romosozumab 10.0 mg/kg SC | Romosozumab 1.0 mg/kg IV | Romosozumab 5.0 mg/kg IV |
|---|---|---|---|---|---|---|---|---|
| Half-life Associated With the Gamma (Terminal) Phase of Elimination for Romosozumab | 5.20 ± 1.36 | 5.13 ± 0.640 | 5.50 ± 0.322 | 6.68 ± 0.961 | 5.81 ± 0.874 | 5.88 ± 1.60 | 4.49 ± 0.974 | 4.93 ± 0.639 |
Defined as the maximum value postdose.
| ng/mL | Placebo SC | Romosozumab 0.1 mg/kg SC | Romosozumab 0.3 mg/kg SC | Romosozumab 1.0 mg/kg SC | Romosozumab 3.0 mg/kg SC | Romosozumab 5.0 mg/kg SC | Romosozumab 10.0 mg/kg SC | Placebo IV | Romosozumab 1.0 mg/kg IV | Romosozumab 5.0 mg/kg IV |
|---|---|---|---|---|---|---|---|---|---|---|
| Maximum Effect for Serum Type 1 Aminoterminal Propeptide (P1NP) | 69.8 ± 32.0 | 57.7 ± 22.8 | 60.9 ± 14.4 | 60.7 ± 10.8 | 100.8 ± 49.6 | 125.1 ± 44.2 | 141.4 ± 24.8 | 77.0 ± 35.3 | 76.3 ± 19.8 | 173.4 ± 43.3 |
Defined as the time to maximum value postdose.
| days | Placebo SC | Romosozumab 0.1 mg/kg SC | Romosozumab 0.3 mg/kg SC | Romosozumab 1.0 mg/kg SC | Romosozumab 3.0 mg/kg SC | Romosozumab 5.0 mg/kg SC | Romosozumab 10.0 mg/kg SC | Placebo IV | Romosozumab 1.0 mg/kg IV | Romosozumab 5.0 mg/kg IV |
|---|---|---|---|---|---|---|---|---|---|---|
| Time to Maximum Effect of P1NP | 39.5 (1.0 to 64.0) | 11.0 (6.0 to 29.0) | 4.5 (1.0 to 15.0) | 15.0 (11.0 to 57.0) | 22.0 (15.0 to 22.0) | 22.0 (15.0 to 29.0) | 25.5 (22.0 to 36.0) | 43.0 (1.0 to 57.0) | 15.0 (11.0 to 22.0) | 18.5 (15.0 to 29.0) |
| days*ng/mL | Placebo SC | Romosozumab 0.1 mg/kg SC | Romosozumab 0.3 mg/kg SC | Romosozumab 1.0 mg/kg SC | Romosozumab 3.0 mg/kg SC | Romosozumab 5.0 mg/kg SC | Romosozumab 10.0 mg/kg SC | Placebo IV | Romosozumab 1.0 mg/kg IV | Romosozumab 5.0 mg/kg IV |
|---|---|---|---|---|---|---|---|---|---|---|
| Area Under the Curve From Day 0 to Day 29 (AUC0-29) for P1NP | 1529 ± 633 | 1431 ± 548 | 1564 ± 377 | 1473 ± 304 | 2300 ± 1099 | 2780 ± 1007 | 2986 ± 306 | 1714 ± 782 | 1794 ± 434 | 3940 ± 944 |
| days*ng/mL | Placebo SC | Romosozumab 0.1 mg/kg SC | Romosozumab 0.3 mg/kg SC | Romosozumab 1.0 mg/kg SC | Romosozumab 3.0 mg/kg SC | Romosozumab 5.0 mg/kg SC | Romosozumab 10.0 mg/kg SC | Placebo IV | Romosozumab 1.0 mg/kg IV | Romosozumab 5.0 mg/kg IV |
|---|---|---|---|---|---|---|---|---|---|---|
| Area Under the Curve From Day 0 to the Last Sampling Time Point (AUC0-t) for P1NP | 3234 ± 1462 | 1431 ± 548 | 1564 ± 377 | 2782 ± 513 | 3962 ± 1702 | 6759 ± 2434 | 7846 ± 1264 | 4487 ± 2352 | 3138 ± 723 | 8976 ± 2531 |
Defined as the minimum value postdose.
| ng/mL | Placebo SC | Romosozumab 0.1 mg/kg SC | Romosozumab 0.3 mg/kg SC | Romosozumab 1.0 mg/kg SC | Romosozumab 3.0 mg/kg SC | Romosozumab 5.0 mg/kg SC | Romosozumab 10.0 mg/kg SC | Placebo IV | Romosozumab 1.0 mg/kg IV | Romosozumab 5.0 mg/kg IV |
|---|---|---|---|---|---|---|---|---|---|---|
| Maximum Effect for Serum C-telopeptide (sCTX) | 0.3 ± 0.2 | 0.4 ± 0.2 | 0.3 ± 0.1 | 0.3 ± 0.1 | 0.4 ± 0.1 | 0.2 ± 0.1 | 0.2 ± 0.1 | 0.3 ± 0.2 | 0.2 ± 0.1 | 0.2 ± 0.1 |
Defined as the time to minimum value postdose.
| days | Placebo SC | Romosozumab 0.1 mg/kg SC | Romosozumab 0.3 mg/kg SC | Romosozumab 1.0 mg/kg SC | Romosozumab 3.0 mg/kg SC | Romosozumab 5.0 mg/kg SC | Romosozumab 10.0 mg/kg SC | Placebo IV | Romosozumab 1.0 mg/kg IV | Romosozumab 5.0 mg/kg IV |
|---|---|---|---|---|---|---|---|---|---|---|
| Time to Maximum Effect of sCTX | 1.0 (1.0 to 36.0) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 43.0) | 1.0 (1.0 to 50.0) | 8.0 (1.0 to 78.0) | 6.0 (1.0 to 22.0) | 18.5 (1.0 to 43.0) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 64.0) |
| days*ng/mL | Placebo SC | Romosozumab 0.1 mg/kg SC | Romosozumab 0.3 mg/kg SC | Romosozumab 1.0 mg/kg SC | Romosozumab 3.0 mg/kg SC | Romosozumab 5.0 mg/kg SC | Romosozumab 10.0 mg/kg SC | Placebo IV | Romosozumab 1.0 mg/kg IV | Romosozumab 5.0 mg/kg IV |
|---|---|---|---|---|---|---|---|---|---|---|
| Area Under the Curve From Day 0 to Day 29 (AUC0-29) for sCTX | 20 ± 8 | 21 ± 6 | 18 ± 5 | 15 ± 6 | 14 ± 3 | 11 ± 4 | 8 ± 3 | 21 ± 8 | 13 ± 3 | 12 ± 5 |
| days*ng/mL | Placebo SC | Romosozumab 0.1 mg/kg SC | Romosozumab 0.3 mg/kg SC | Romosozumab 1.0 mg/kg SC | Romosozumab 3.0 mg/kg SC | Romosozumab 5.0 mg/kg SC | Romosozumab 10.0 mg/kg SC | Placebo IV | Romosozumab 1.0 mg/kg IV | Romosozumab 5.0 mg/kg IV |
|---|---|---|---|---|---|---|---|---|---|---|
| Area Under the Curve From Day 0 to the Last Sampling Time Point (AUC0-t) for sCTX | 37 ± 18 | 21 ± 6 | 18 ± 5 | 30 ± 13 | 29 ± 7 | 41 ± 18 | 40 ± 15 | 44 ± 20 | 26 ± 6 | 44 ± 13 |
Defined as the maximum value postdose.
| µg/L | Placebo SC | Romosozumab 0.1 mg/kg SC | Romosozumab 0.3 mg/kg SC | Romosozumab 1.0 mg/kg SC | Romosozumab 3.0 mg/kg SC | Romosozumab 5.0 mg/kg SC | Romosozumab 10.0 mg/kg SC | Placebo IV | Romosozumab 1.0 mg/kg IV | Romosozumab 5.0 mg/kg IV |
|---|---|---|---|---|---|---|---|---|---|---|
| Maximum Effect for Osteocalcin | 28.9 ± 8.1 | 25.6 ± 8.0 | 25.8 ± 4.8 | 26.6 ± 5.5 | 36.9 ± 10.9 | 39.0 ± 12.7 | 53.9 ± 10.5 | 35.9 ± 13.9 | 28.8 ± 7.7 | 53.5 ± 12.8 |
Defined as the time to maximum value postdose.
| days | Placebo SC | Romosozumab 0.1 mg/kg SC | Romosozumab 0.3 mg/kg SC | Romosozumab 1.0 mg/kg SC | Romosozumab 3.0 mg/kg SC | Romosozumab 5.0 mg/kg SC | Romosozumab 10.0 mg/kg SC | Placebo IV | Romosozumab 1.0 mg/kg IV | Romosozumab 5.0 mg/kg IV |
|---|---|---|---|---|---|---|---|---|---|---|
| Time to Maximum Effect of Osteocalcin | 29.0 (2.0 to 57.0) | 15.0 (2.0 to 15.0) | 18.5 (2.0 to 38.0) | 22.0 (11.0 to 36.0) | 22.0 (22.0 to 29.0) | 29.0 (29.0 to 50.0) | 36.0 (26.0 to 57.0) | 34.0 (5.0 to 64.0) | 22.0 (11.0 to 36.0) | 32.5 (29.0 to 43.0) |
| days*µg/L | Placebo SC | Romosozumab 0.1 mg/kg SC | Romosozumab 0.3 mg/kg SC | Romosozumab 1.0 mg/kg SC | Romosozumab 3.0 mg/kg SC | Romosozumab 5.0 mg/kg SC | Romosozumab 10.0 mg/kg SC | Placebo IV | Romosozumab 1.0 mg/kg IV | Romosozumab 5.0 mg/kg IV |
|---|---|---|---|---|---|---|---|---|---|---|
| Area Under the Curve From Day 0 to Day 29 (AUC0-29) for Osteocalcin | 617 ± 209 | 611 ± 191 | 658 ± 153 | 570 ± 139 | 753 ± 234 | 757 ± 225 | 881 ± 162 | 759 ± 286 | 559 ± 73 | 973 ± 212 |
| days*µg/L | Placebo SC | Romosozumab 0.1 mg/kg SC | Romosozumab 0.3 mg/kg SC | Romosozumab 1.0 mg/kg SC | Romosozumab 3.0 mg/kg SC | Romosozumab 5.0 mg/kg SC | Romosozumab 10.0 mg/kg SC | Placebo IV | Romosozumab 1.0 mg/kg IV | Romosozumab 5.0 mg/kg IV |
|---|---|---|---|---|---|---|---|---|---|---|
| Area Under the Curve From Day 0 to the Last Sampling Time Point (AUC0-t) for Osteocalcin | 1259 ± 505 | 611 ± 191 | 658 ± 153 | 1129 ± 256 | 1487 ± 453 | 2470 ± 827 | 2964 ± 563 | 1897 ± 519 | 1132 ± 131 | 2988 ± 460 |
Defined as the maximum value postdose.
| µg/L | Placebo SC | Romosozumab 0.1 mg/kg SC | Romosozumab 0.3 mg/kg SC | Romosozumab 1.0 mg/kg SC | Romosozumab 3.0 mg/kg SC | Romosozumab 5.0 mg/kg SC | Romosozumab 10.0 mg/kg SC | Placebo IV | Romosozumab 1.0 mg/kg IV | Romosozumab 5.0 mg/kg IV |
|---|---|---|---|---|---|---|---|---|---|---|
| Maximum Effect for Bone-specific Alkaline Phosphatase (BSAP) | 21.0 ± 5.7 | 18.0 ± 6.7 | 17.2 ± 3.2 | 17.7 ± 4.7 | 26.1 ± 7.8 | 24.6 ± 8.6 | 29.9 ± 8.2 | 19.6 ± 3.7 | 15.9 ± 4.5 | 36.4 ± 15.9 |
Defined as the time to maximum value postdose.
| days | Placebo SC | Romosozumab 0.1 mg/kg SC | Romosozumab 0.3 mg/kg SC | Romosozumab 1.0 mg/kg SC | Romosozumab 3.0 mg/kg SC | Romosozumab 5.0 mg/kg SC | Romosozumab 10.0 mg/kg SC | Placebo IV | Romosozumab 1.0 mg/kg IV | Romosozumab 5.0 mg/kg IV |
|---|---|---|---|---|---|---|---|---|---|---|
| Time to Maximum Effect of BSAP | 36.0 (4.0 to 78.0) | 16.5 (4.0 to 29.0) | 13.0 (6.0 to 19.0) | 15.0 (8.0 to 29.0) | 22.0 (22.0 to 22.0) | 22.0 (22.0 to 36.0) | 22.0 (15.0 to 29.0) | 46.5 (6.0 to 85.0) | 13.5 (6.0 to 50.0) | 29.0 (22.0 to 36.0) |
| days*µg/L | Placebo SC | Romosozumab 0.1 mg/kg SC | Romosozumab 0.3 mg/kg SC | Romosozumab 1.0 mg/kg SC | Romosozumab 3.0 mg/kg SC | Romosozumab 5.0 mg/kg SC | Romosozumab 10.0 mg/kg SC | Placebo IV | Romosozumab 1.0 mg/kg IV | Romosozumab 5.0 mg/kg IV |
|---|---|---|---|---|---|---|---|---|---|---|
| Area Under the Curve From Day 0 to Day 29 (AUC0-29) for BSAP | 462 ± 157 | 460 ± 172 | 460 ± 127 | 422 ± 100 | 588 ± 152 | 540 ± 210 | 639 ± 176 | 448 ± 73 | 376 ± 102 | 780 ± 325 |
| days*µg/L | Placebo SC | Romosozumab 0.1 mg/kg SC | Romosozumab 0.3 mg/kg SC | Romosozumab 1.0 mg/kg SC | Romosozumab 3.0 mg/kg SC | Romosozumab 5.0 mg/kg SC | Romosozumab 10.0 mg/kg SC | Placebo IV | Romosozumab 1.0 mg/kg IV | Romosozumab 5.0 mg/kg IV |
|---|---|---|---|---|---|---|---|---|---|---|
| Area Under the Curve From Day 0 to the Last Sampling Time Point (AUC0-t) for BSAP | 958 ± 428 | 460 ± 172 | 460 ± 127 | 815 ± 190 | 1120 ± 303 | 1496 ± 527 | 1860 ± 508 | 1138 ± 191 | 731 ± 177 | 2033 ± 780 |
Defined as the maximum value postdose.
| ng/L | Placebo SC | Romosozumab 0.1 mg/kg SC | Romosozumab 0.3 mg/kg SC | Romosozumab 1.0 mg/kg SC | Romosozumab 3.0 mg/kg SC | Romosozumab 5.0 mg/kg SC | Romosozumab 10.0 mg/kg SC | Placebo IV | Romosozumab 1.0 mg/kg IV | Romosozumab 5.0 mg/kg IV |
|---|---|---|---|---|---|---|---|---|---|---|
| Maximum Effect for Intact Parathyroid Hormone (iPTH) | 43.3 ± 12.6 | 38.7 ± 11.9 | 54.5 ± 13.1 | 49.9 ± 20.5 | 62.8 ± 10.9 | 66.0 ± 20.0 | 76.3 ± 15.7 | 64.8 ± 27.8 | 52.7 ± 20.1 | 59.7 ± 14.9 |
Defined as the time to maximum value postdose.
| days | Placebo SC | Romosozumab 0.1 mg/kg SC | Romosozumab 0.3 mg/kg SC | Romosozumab 1.0 mg/kg SC | Romosozumab 3.0 mg/kg SC | Romosozumab 5.0 mg/kg SC | Romosozumab 10.0 mg/kg SC | Placebo IV | Romosozumab 1.0 mg/kg IV | Romosozumab 5.0 mg/kg IV |
|---|---|---|---|---|---|---|---|---|---|---|
| Time to Maximum Effect of iPTH | 11.0 (1.0 to 71.0) | 11.0 (1.0 to 15.0) | 25.5 (15.0 to 29.0) | 22.0 (3.0 to 43.0) | 22.0 (1.0 to 29.0) | 22.0 (8.0 to 50.0) | 15.0 (1.0 to 50.0) | 25.5 (1.0 to 71.0) | 11.0 (1.0 to 57.0) | 18.5 (8.0 to 43.0) |
| days*ng/L | Placebo SC | Romosozumab 0.1 mg/kg SC | Romosozumab 0.3 mg/kg SC | Romosozumab 1.0 mg/kg SC | Romosozumab 3.0 mg/kg SC | Romosozumab 5.0 mg/kg SC | Romosozumab 10.0 mg/kg SC | Placebo IV | Romosozumab 1.0 mg/kg IV | Romosozumab 5.0 mg/kg IV |
|---|---|---|---|---|---|---|---|---|---|---|
| Area Under the Curve From Day 0 to Day 29 (AUC0-29) for iPTH | 817 ± 295 | 823 ± 202 | 1234 ± 341 | 1002 ± 405 | 1270 ± 198 | 1240 ± 342 | 1422 ± 411 | 1235 ± 488 | 1074 ± 406 | 1239 ± 267 |
| days*ng/L | Placebo SC | Romosozumab 0.1 mg/kg SC | Romosozumab 0.3 mg/kg SC | Romosozumab 1.0 mg/kg SC | Romosozumab 3.0 mg/kg SC | Romosozumab 5.0 mg/kg SC | Romosozumab 10.0 mg/kg SC | Placebo IV | Romosozumab 1.0 mg/kg IV | Romosozumab 5.0 mg/kg IV |
|---|---|---|---|---|---|---|---|---|---|---|
| Area Under the Curve From Day 0 to the Last Sampling Timepoint (AUC0-t) for iPTH | 1592 ± 689 | 823 ± 202 | 1234 ± 341 | 1971 ± 850 | 2523 ± 406 | 3483 ± 1057 | 4195 ± 1144 | 3100 ± 1077 | 2072 ± 749 | 3515 ± 1127 |
| percent change | Placebo SC | Romosozumab 0.1 mg/kg SC | Romosozumab 0.3 mg/kg SC | Romosozumab 1.0 mg/kg SC | Romosozumab 3.0 mg/kg SC | Romosozumab 5.0 mg/kg SC | Romosozumab 10.0 mg/kg SC | Placebo IV | Romosozumab 1.0 mg/kg IV | Romosozumab 5.0 mg/kg IV |
|---|---|---|---|---|---|---|---|---|---|---|
| Day 15 | 53.2 ± 54.3 | 465.5 ± 49.9 | 835.1 ± 130.4 | 2123.8 ± 377.6 | 7965.9 ± 792.9 | 12375.7 ± 1375.4 | 17774.8 ± 2444.0 | 6.7 ± 11.4 | 3776.0 ± 461.5 | 14230.0 ± 2428.1 |
| Day 29 | -8.4 ± 7.0 | 129.0 ± 33.3 | 183.0 ± 19.6 | 717.4 ± 92.4 | 5140.2 ± 373.7 | 9763.2 ± 1252.8 | 18870.9 ± 2707.3 | -4.3 ± 8.7 | 816.7 ± 222.3 | 11715.5 ± 2177.0 |
| Day 43 | -9.8 ± 14.1 | — | — | 223.2 ± 18.1 | 1988.3 ± 339.9 | 4968.7 ± 714.7 | 13902.7 ± 2381.9 | 4.9 ± 8.7 | 196.1 ± 48.7 | 4576.0 ± 1086.7 |
| Day 57 | -3.7 ± 8.6 | — | — | 83.4 ± 14.5 | 810.2 ± 169.9 | 2004.9 ± 421.5 | 6469.6 ± 1000.3 | 15.6 ± 0.6 | 49.9 ± 17.4 | 1430.0 ± 538.0 |
| Day 71 | 86.9 ± 88.3 | — | — | — | — | 610.4 ± 151.6 | 2080.8 ± 689.0 | -5.5 ± 5.4 | — | 426.9 ± 119.6 |
| Day 85 | 11.6 ± 16.6 | — | — | — | — | 232.1 ± 49.0 | 758.0 ± 270.1 | 0.8 ± 13.4 | — | 109.8 ± 30.6 |
| mg/dL | Placebo SC | Romosozumab 0.1 mg/kg SC | Romosozumab 0.3 mg/kg SC | Romosozumab 1.0 mg/kg SC | Romosozumab 3.0 mg/kg SC | Romosozumab 5.0 mg/kg SC | Romosozumab 10.0 mg/kg SC | Placebo IV | Romosozumab 1.0 mg/kg IV | Romosozumab 5.0 mg/kg IV |
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 Pre-dose | 9.49 ± 0.34 | 9.45 ± 0.38 | 9.50 ± 0.33 | 9.48 ± 0.27 | 9.42 ± 0.25 | 9.53 ± 0.26 | 9.38 ± 0.24 | 9.60 ± 0.22 | 9.23 ± 0.15 | 9.37 ± 0.15 |
| Day 1 Hour 4 | 9.46 ± 0.30 | 9.62 ± 0.19 | 9.45 ± 0.26 | 9.38 ± 0.16 | 9.38 ± 0.15 | 9.59 ± 0.27 | 9.35 ± 0.40 | 9.45 ± 0.21 | 9.43 ± 0.22 | 9.40 ± 0.17 |
| Day 1 Hour 6 | 9.49 ± 0.26 | 9.38 ± 0.22 | 9.50 ± 0.14 | 9.47 ± 0.17 | 9.60 ± 0.24 | 9.48 ± 0.35 | 9.25 ± 0.36 | 9.18 ± 0.13 | 9.38 ± 0.31 | 9.40 ± 0.15 |
| Day 1 Hour 8 | 9.38 ± 0.22 | 9.47 ± 0.29 | 9.33 ± 0.23 | 9.29 ± 0.18 | 9.28 ± 0.12 | 9.42 ± 0.28 | 9.27 ± 0.33 | 9.38 ± 0.21 | 9.35 ± 0.10 | 9.22 ± 0.12 |
| Day 1 Hour 10 | 9.53 ± 0.26 | 9.62 ± 0.31 | 9.50 ± 0.27 | 9.40 ± 0.30 | 9.38 ± 0.19 | 9.36 ± 0.31 | 9.28 ± 0.27 | 9.50 ± 0.22 | 9.45 ± 0.16 | 9.42 ± 0.15 |
| Day 1 Hour 12 | 9.53 ± 0.28 | 9.55 ± 0.27 | 9.57 ± 0.31 | 9.49 ± 0.31 | 9.37 ± 0.34 | 9.52 ± 0.26 | 9.27 ± 0.34 | 9.40 ± 0.24 | 9.47 ± 0.19 | 9.45 ± 0.19 |
| Day 2 | 9.46 ± 0.34 | 9.55 ± 0.21 | 9.23 ± 0.28 | 9.39 ± 0.21 | 9.37 ± 0.33 | 9.46 ± 0.29 | 9.23 ± 0.29 | 8.55 ± 1.77 | 9.05 ± 0.41 | 9.28 ± 0.15 |
| Day 3 | 9.30 ± 0.61 | 9.37 ± 0.29 | 9.25 ± 0.39 | 9.20 ± 0.34 | 9.35 ± 0.14 | 9.38 ± 0.41 | 9.18 ± 0.17 | 9.40 ± 0.24 | 9.13 ± 0.51 | 9.27 ± 0.18 |
| Day 4 | 9.49 ± 0.25 | 9.38 ± 0.27 | 9.37 ± 0.27 | 9.18 ± 0.64 | 9.27 ± 0.12 | 9.40 ± 0.30 | 9.13 ± 0.22 | 9.23 ± 0.50 | 8.88 ± 0.84 | 9.18 ± 0.13 |
| Day 5 | 9.42 ± 0.36 | 9.38 ± 0.21 | 9.37 ± 0.25 | 9.38 ± 0.24 | 9.32 ± 0.25 | 9.24 ± 0.26 | 9.15 ± 0.18 | 9.55 ± 0.17 | 9.20 ± 0.15 | 9.12 ± 0.19 |
| Day 6 | 9.56 ± 0.26 | 9.45 ± 0.29 | 9.45 ± 0.26 | 9.51 ± 0.20 | 9.35 ± 0.10 | 9.36 ± 0.26 | 9.18 ± 0.15 | 9.35 ± 0.24 | 9.32 ± 0.19 | 9.23 ± 0.12 |
| Day 8 | 9.41 ± 0.31 | 9.45 ± 0.20 | 9.28 ± 0.23 | 9.36 ± 0.44 | 9.23 ± 0.10 | 9.33 ± 0.40 | 8.93 ± 0.28 | 9.30 ± 0.22 | 9.18 ± 0.29 | 9.20 ± 0.37 |
| Day 11 | 9.32 ± 0.29 | 9.38 ± 0.33 | 9.07 ± 0.24 | 9.39 ± 0.25 | 9.30 ± 0.39 | 9.19 ± 0.36 | 8.70 ± 0.75 | 9.30 ± 0.22 | 9.13 ± 0.29 | 9.18 ± 0.26 |
| Day 15 | 9.39 ± 0.26 | 9.60 ± 0.17 | 9.40 ± 0.32 | 9.26 ± 0.21 | 9.22 ± 0.19 | 9.06 ± 0.35 | 8.97 ± 0.18 | 9.33 ± 0.22 | 9.28 ± 0.33 | 9.00 ± 0.36 |
| Day 22 | 9.35 ± 0.33 | 9.53 ± 0.45 | 9.18 ± 0.35 | 9.33 ± 0.32 | 9.22 ± 0.17 | 9.14 ± 0.47 | 8.90 ± 0.23 | 9.48 ± 0.13 | 9.18 ± 0.22 | 9.08 ± 0.15 |
| Day 29 | 9.49 ± 0.32 | 9.58 ± 0.22 | 9.40 ± 0.26 | 9.44 ± 0.37 | 9.20 ± 0.27 | 9.32 ± 0.28 | 8.95 ± 0.19 | 9.38 ± 0.13 | 9.17 ± 0.21 | 9.15 ± 0.23 |
| Day 36 | 9.40 ± 0.45 | — | — | 9.33 ± 0.26 | 9.23 ± 0.30 | 9.00 ± 0.26 | 9.07 ± 0.26 | 9.25 ± 0.30 | 9.18 ± 0.35 | 9.00 ± 0.30 |
| Day 43 | 9.33 ± 0.39 | — | — | 9.32 ± 0.21 | 9.37 ± 0.31 | 9.23 ± 0.36 | 8.90 ± 0.26 | 9.28 ± 0.33 | 9.25 ± 0.25 | 9.15 ± 0.33 |
| Day 50 | 9.35 ± 0.26 | — | — | 9.30 ± 0.41 | 9.03 ± 0.21 | 9.40 ± 0.34 | 8.98 ± 0.19 | 9.33 ± 0.33 | 9.43 ± 0.50 | 9.07 ± 0.23 |
| Day 57 | 9.46 ± 0.30 | — | — | 9.47 ± 0.36 | 9.35 ± 0.29 | 9.18 ± 0.49 | 9.28 ± 0.17 | 9.33 ± 0.29 | 9.25 ± 0.27 | 9.02 ± 0.21 |
| Day 64 | 9.22 ± 0.15 | — | — | — | — | 9.28 ± 0.42 | 8.90 ± 0.36 | 9.25 ± 0.07 | — | 9.18 ± 0.35 |
| Day 71 | 9.36 ± 0.18 | — | — | — | — | 9.47 ± 0.47 | 9.05 ± 0.36 | 9.20 ± 0.14 | — | 9.20 ± 0.14 |
| Day 78 | 9.30 ± 0.24 | — | — | — | — | 9.31 ± 0.32 | 9.07 ± 0.40 | 9.20 ± 0.00 | — | 9.12 ± 0.34 |
| Day 85 | 9.12 ± 0.08 | — | — | — | — | 9.47 ± 0.35 | 8.82 ± 0.31 | 9.10 ± 0.28 | — | 9.05 ± 0.26 |
| mg/dL | Placebo SC | Romosozumab 0.1 mg/kg SC | Romosozumab 0.3 mg/kg SC | Romosozumab 1.0 mg/kg SC | Romosozumab 3.0 mg/kg SC | Romosozumab 5.0 mg/kg SC | Romosozumab 10.0 mg/kg SC | Placebo IV | Romosozumab 1.0 mg/kg IV | Romosozumab 5.0 mg/kg IV |
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 Pre-dose | 5.02 ± 0.20 | 4.95 ± 0.18 | 5.02 ± 0.16 | 5.01 ± 0.18 | 4.88 ± 0.08 | 5.07 ± 0.18 | 4.85 ± 0.10 | 5.30 ± 0.12 | 5.18 ± 0.15 | 5.27 ± 0.15 |
| Day 1 Hour 4 | 5.06 ± 0.20 | 5.02 ± 0.17 | 5.10 ± 0.13 | 5.11 ± 0.24 | 5.03 ± 0.10 | 5.12 ± 0.32 | 4.95 ± 0.08 | 5.40 ± 0.14 | 5.35 ± 0.18 | 5.40 ± 0.09 |
| Day 1 Hour 6 | 4.97 ± 0.19 | 4.93 ± 0.10 | 4.98 ± 0.10 | 4.97 ± 0.21 | 4.93 ± 0.08 | 5.06 ± 0.24 | 4.87 ± 0.12 | 5.10 ± 0.14 | 5.28 ± 0.15 | 5.30 ± 0.09 |
| Day 1 Hour 8 | 4.93 ± 0.14 | 4.92 ± 0.15 | 5.00 ± 0.11 | 5.00 ± 0.21 | 4.90 ± 0.06 | 5.04 ± 0.27 | 4.78 ± 0.12 | 5.30 ± 0.08 | 5.28 ± 0.17 | 5.30 ± 0.09 |
| Day 1 Hour 10 | 5.06 ± 0.20 | 5.00 ± 0.09 | 5.05 ± 0.10 | 5.11 ± 0.19 | 4.95 ± 0.15 | 5.07 ± 0.34 | 4.88 ± 0.12 | 5.30 ± 0.12 | 5.32 ± 0.18 | 5.38 ± 0.15 |
| Day 1 Hour 12 | 5.01 ± 0.18 | 4.95 ± 0.08 | 5.00 ± 0.15 | 5.01 ± 0.20 | 4.93 ± 0.16 | 5.03 ± 0.30 | 4.80 ± 0.11 | 5.28 ± 0.22 | 5.25 ± 0.10 | 5.33 ± 0.08 |
| Day 2 | 5.04 ± 0.20 | 5.03 ± 0.16 | 4.92 ± 0.17 | 5.03 ± 0.17 | 4.98 ± 0.12 | 5.04 ± 0.19 | 4.88 ± 0.15 | 5.28 ± 0.10 | 5.08 ± 0.08 | 5.18 ± 0.10 |
| Day 3 | 5.06 ± 0.19 | 5.00 ± 0.13 | 4.97 ± 0.14 | 5.00 ± 0.14 | 4.95 ± 0.08 | 5.12 ± 0.20 | 4.85 ± 0.05 | 5.28 ± 0.13 | 5.17 ± 0.12 | 5.25 ± 0.14 |
| Day 4 | 5.05 ± 0.17 | 4.97 ± 0.15 | 4.85 ± 0.16 | 5.03 ± 0.10 | 4.87 ± 0.12 | 5.11 ± 0.20 | 4.82 ± 0.08 | 5.23 ± 0.17 | 5.20 ± 0.09 | 5.17 ± 0.14 |
| Day 5 | 5.02 ± 0.18 | 4.93 ± 0.10 | 4.88 ± 0.25 | 5.04 ± 0.12 | 4.93 ± 0.12 | 5.04 ± 0.19 | 4.80 ± 0.06 | 5.40 ± 0.14 | 5.18 ± 0.12 | 5.15 ± 0.14 |
| Day 6 | 5.02 ± 0.16 | 4.91 ± 0.14 | 4.97 ± 0.12 | 5.06 ± 0.11 | 4.88 ± 0.10 | 5.02 ± 0.14 | 4.80 ± 0.06 | 5.23 ± 0.10 | 5.23 ± 0.12 | 5.05 ± 0.10 |
| Day 8 | 5.02 ± 0.17 | 4.98 ± 0.08 | 4.92 ± 0.10 | 5.01 ± 0.24 | 4.83 ± 0.10 | 4.89 ± 0.18 | 5.00 ± 0.14 | 5.23 ± 0.17 | 5.17 ± 0.12 | 5.07 ± 0.19 |
| Day 11 | 5.01 ± 0.14 | 5.05 ± 0.14 | 4.93 ± 0.14 | 5.06 ± 0.17 | 4.90 ± 0.13 | 4.92 ± 0.15 | 5.00 ± 0.11 | 5.23 ± 0.13 | 5.20 ± 0.13 | 5.10 ± 0.20 |
| Day 15 | 5.05 ± 0.16 | 5.10 ± 0.19 | 4.92 ± 0.12 | 5.02 ± 0.16 | 4.83 ± 0.12 | 4.98 ± 0.19 | 5.00 ± 0.06 | 5.20 ± 0.22 | 5.25 ± 0.12 | 5.07 ± 0.12 |
| Day 22 | 5.03 ± 0.17 | 5.05 ± 0.18 | 4.82 ± 0.12 | 4.92 ± 0.16 | 4.85 ± 0.08 | 5.08 ± 0.17 | 5.05 ± 0.08 | 5.18 ± 0.24 | 5.12 ± 0.15 | 5.05 ± 0.21 |
| Day 29 | 5.13 ± 0.17 | 5.05 ± 0.08 | 4.92 ± 0.17 | 5.02 ± 0.20 | 4.85 ± 0.08 | 5.22 ± 0.12 | 5.03 ± 0.16 | 5.28 ± 0.17 | 5.22 ± 0.10 | 5.13 ± 0.20 |
| Day 36 | 5.16 ± 0.17 | — | — | 4.96 ± 0.14 | 5.07 ± 0.16 | 5.11 ± 0.18 | 4.96 ± 0.16 | 5.28 ± 0.13 | 5.18 ± 0.10 | 5.18 ± 0.15 |
| Day 43 | 5.18 ± 0.23 | — | — | 4.99 ± 0.15 | 5.22 ± 0.13 | 5.26 ± 0.21 | 5.02 ± 0.08 | 5.23 ± 0.17 | 5.30 ± 0.13 | 5.18 ± 0.12 |
| Day 50 | 5.21 ± 0.19 | — | — | 5.19 ± 0.16 | 5.20 ± 0.11 | 5.16 ± 0.11 | 5.00 ± 0.13 | 5.28 ± 0.15 | 5.32 ± 0.13 | 5.15 ± 0.14 |
| Day 57 | 5.26 ± 0.14 | — | — | 5.22 ± 0.14 | 5.22 ± 0.10 | 5.21 ± 0.15 | 5.18 ± 0.13 | 5.33 ± 0.17 | 5.23 ± 0.08 | 5.25 ± 0.15 |
| Day 64 | 5.18 ± 0.11 | — | — | — | — | 5.22 ± 0.18 | 5.13 ± 0.14 | 5.15 ± 0.07 | — | 5.17 ± 0.14 |
| Day 71 | 5.18 ± 0.08 | — | — | — | — | 5.38 ± 0.16 | 5.12 ± 0.18 | 5.30 ± 0.28 | — | 5.20 ± 0.13 |
| Day 78 | 5.28 ± 0.08 | — | — | — | — | 5.30 ± 0.17 | 5.15 ± 0.19 | 5.15 ± 0.07 | — | 5.27 ± 0.15 |
| Day 85 | 5.24 ± 0.11 | — | — | — | — | 5.36 ± 0.13 | 5.13 ± 0.22 | 5.20 ± 0.14 | — | 5.23 ± 0.14 |
Collected over Adverse events were collected from the first dose of treatment up until day 29 for the 0.1 mg/kg and 0.3 mg/kg SC treatment groups, up to 57 days for the 1 mg/kg and 3 mg/kg IV/SC groups and for up to 85 days for the 5 mg/kg and 10 mg/kg SC/IV groups.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo SC | — | 0/14 (0%) | 9/14 (64.3%) |
| Placebo IV | — | 0/4 (0%) | 2/4 (50%) |
| Romosozumab 0.1 mg/kg SC | — | 0/6 (0%) | 4/6 (66.7%) |
| Romosozumab 0.3 mg/kg SC | — | 0/6 (0%) | 4/6 (66.7%) |
| Romosozumab 1.0 mg/kg SC | — | 0/9 (0%) | 1/9 (11.1%) |
| Romosozumab 10.0 mg/kg SC | — | 1/6 (16.7%) | 5/6 (83.3%) |
| Romosozumab 3.0 mg/kg SC | — | 0/6 (0%) | 5/6 (83.3%) |
| Romosozumab 5.0 mg/kg SC | — | 0/9 (0%) | 6/9 (66.7%) |
| Romosozumab 1.0 mg/kg IV | — | 0/6 (0%) | 1/6 (16.7%) |
| Romosozumab 5.0 mg/kg IV | — | 0/6 (0%) | 2/6 (33.3%) |
| Event | Placebo SC | Placebo IV | Romosozumab 0.1 mg/kg SC | Romosozumab 0.3 mg/kg SC | Romosozumab 1.0 mg/kg SC | Romosozumab 10.0 mg/kg SC | Romosozumab 3.0 mg/kg SC | Romosozumab 5.0 mg/kg SC | Romosozumab 1.0 mg/kg IV | Romosozumab 5.0 mg/kg IV |
|---|---|---|---|---|---|---|---|---|---|---|
| HEPATITISHepatobiliary disorders | 0/14 | 0/4 | 0/6 | 0/6 | 0/9 | 1/6 | 0/6 | 0/9 | 0/6 | 0/6 |
| Event | Placebo SC | Placebo IV | Romosozumab 0.1 mg/kg SC | Romosozumab 0.3 mg/kg SC | Romosozumab 1.0 mg/kg SC | Romosozumab 10.0 mg/kg SC | Romosozumab 3.0 mg/kg SC | Romosozumab 5.0 mg/kg SC | Romosozumab 1.0 mg/kg IV | Romosozumab 5.0 mg/kg IV |
|---|---|---|---|---|---|---|---|---|---|---|
| INJECTION SITE ERYTHEMAGeneral disorders | 0/14 | 0/4 | 0/6 | 1/6 | 0/9 | 4/6 | 2/6 | 2/9 | 0/6 | 0/6 |
| DIARRHOEAGastrointestinal disorders | 0/14 | 0/4 | 2/6 | 0/6 | 0/9 | 0/6 | 0/6 | 0/9 | 0/6 | 0/6 |
| BACK PAINMusculoskeletal and connective tissue disorders | 1/14 | 0/4 | 1/6 | 0/6 | 0/9 | 2/6 | 0/6 | 1/9 | 0/6 | 0/6 |
| HEADACHENervous system disorders | 3/14 | 0/4 | 1/6 | 0/6 | 0/9 | 2/6 | 0/6 | 1/9 | 1/6 | 0/6 |
| CONSTIPATIONGastrointestinal disorders | 1/14 | 1/4 | 0/6 | 0/6 | 0/9 | 1/6 | 0/6 | 2/9 | 0/6 | 1/6 |
| ESCHERICHIA URINARY TRACT INFECTIONInfections and infestations | 0/14 | 1/4 | 0/6 | 0/6 | 0/9 | 0/6 | 0/6 | 0/9 | 0/6 | 0/6 |
| URINARY TRACT INFECTIONInfections and infestations | 0/14 | 1/4 | 0/6 | 0/6 | 0/9 | 1/6 | 0/6 | 1/9 | 0/6 | 0/6 |
| DECREASED APPETITEMetabolism and nutrition disorders | 0/14 | 1/4 | 0/6 | 0/6 | 0/9 | 0/6 | 0/6 | 0/9 | 0/6 | 0/6 |
| INJECTION SITE HAEMORRHAGEGeneral disorders | 0/14 | 0/4 | 0/6 | 0/6 | 0/9 | 1/6 | 0/6 | 2/9 | 0/6 | 0/6 |
| MUSCLE SPASMSMusculoskeletal and connective tissue disorders | 0/14 | 0/4 | 0/6 | 0/6 | 0/9 | 0/6 | 0/6 | 2/9 | 0/6 | 0/6 |
All treated participants
| Age, Continuous(years) | Placebo SC | Romosozumab 0.1 mg/kg SC | Romosozumab 0.3 mg/kg SC | Romosozumab 1.0 mg/kg SC | Romosozumab 3.0 mg/kg SC | Romosozumab 5.0 mg/kg SC | Romosozumab 10.0 mg/kg SC | Placebo IV | Romosozumab 1.0 mg/kg IV | Romosozumab 5.0 mg/kg IV | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SC Dosing | 52.79 ± 4.17 | 53.00 ± 3.95 | 53.33 ± 3.20 | 52.00 ± 4.64 | 55.00 ± 4.05 | 51.89 ± 2.32 | 52.50 ± 4.32 | NA ± NA | NA ± NA | NA ± NA | 52.80 ± 3.79 |
| IV Dosing | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 52.50 ± 4.43 | 49.33 ± 4.63 | 51.00 ± 3.35 | 50.75 ± 4.06 |
| Sex: Female, Male(Participants) | Placebo SC | Romosozumab 0.1 mg/kg SC | Romosozumab 0.3 mg/kg SC | Romosozumab 1.0 mg/kg SC | Romosozumab 3.0 mg/kg SC | Romosozumab 5.0 mg/kg SC | Romosozumab 10.0 mg/kg SC | Placebo IV | Romosozumab 1.0 mg/kg IV | Romosozumab 5.0 mg/kg IV | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 12 | 6 | 6 | 6 | 6 | 6 | 6 | 2 | 3 | 3 | 56 |
| Male | 2 | 0 | 0 | 3 | 0 | 3 | 0 | 2 | 3 | 3 | 16 |
| Race/Ethnicity, Customized(Participants) | Placebo SC | Romosozumab 0.1 mg/kg SC | Romosozumab 0.3 mg/kg SC | Romosozumab 1.0 mg/kg SC | Romosozumab 3.0 mg/kg SC | Romosozumab 5.0 mg/kg SC | Romosozumab 10.0 mg/kg SC | Placebo IV | Romosozumab 1.0 mg/kg IV | Romosozumab 5.0 mg/kg IV | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| White or Caucasian | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 0 | 6 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Hispanic or Latino | 12 | 6 | 6 | 9 | 6 | 9 | 5 | 2 | 4 | 6 | 65 |
No study locations are listed for this record.
Ran from Dec 2006 to primary completion in Jul 2007, 6 months.
Results were first posted in Jul 2019, 11 years 11 months after primary completion.
Of 13 phase 1 interventional studies under Bone Diseases, Metabolic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 37. This study's 6 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Romosozumab